C ancer patients often experience pain that spans across the history of the disease. Cancer pain remains a major healthcare problem worldwide 1 despite advances in cancer treatment and cancer-related pain management. A systematic review of the prevalence and/or incidence of cancer-related pain demonstrated that a significant number (960% to 990%) of patients with advanced cancer worldwide experience pain that requires treatment.
C
ancer patients often experience pain that spans across the history of the disease. Cancer pain remains a major healthcare problem worldwide 1 despite advances in cancer treatment and cancer-related pain management. A systematic review of the prevalence and/or incidence of cancer-related pain demonstrated that a significant number (960% to 990%) of patients with advanced cancer worldwide experience pain that requires treatment. 2 In addition to pain, many people with cancer experience psychological symptoms that together result in a diminished quality of life. 3 In Taiwan, pain was the second commonest symptom experienced by advanced cancer patients. 4 Increasingly, complementary therapies that can help improve both physical and psychological well-being have been advocated to be integrated with conventional therapies because most cancer patients are not satisfied with mainstream treatments in relieving these symptoms. 5 The National Comprehensive Cancer Network guidelines for the management of adult cancer pain recommend adopting nonpharmacological therapies such as massage, acupuncture/acupressure, guided imagery, relaxation training, and cognitive behavioral training if pain scores remain at 4 or above on a 10-point scale after reevaluation and modification of pharmacological management. 6 Complementary and alternative medicine is of considerable interest to the adult population. Reportedly, relaxation techniques were the second most frequently used of all complementary and alternative medicine modalities by adult general population 7, 8 and by cancer patients receiving treatment. 9 The beneficial use of the relaxation response has been demonstrated in various disease states. 10 Few controlled studies have examined the effect of relaxation interventions on the management of cancer pain, in particular, or end-oflife symptoms, in general. Previous systematic reviews revealed that there was insufficient evidence to support the efficacy of relaxation for the relief of cancer-related pain 11 or chronic pain at large. 12 On the contrary, a meta-analysis found significant beneficial effects of relaxation in cancer patients for reducing cancer treatmentYrelated pain, with an average effect size of 0.44. 13 For relaxation training to gain acceptance by the medical community in palliative care as a legitimate treatment modality, it is important to identify effective treatment components and underlying therapeutic mechanisms in advanced cancer patients.
Frontalis electromyography (EMG) has been widely used in clinical biofeedback for stress reduction. 14, 15 However, studies examining the effect of frontalis EMG biofeedback was composed mostly of case reports and uncontrolled studies. 15 Surface EMG can be a useful modality in assisting individuals to achieve a desired relaxation response that may help break the pain-anxiety-muscle tension cycle. To date, the application of relaxation interventions in the advanced cancer patients is still understudied. We therefore designed this study to examine the effect of EMG biofeedbackYassisted relaxation on cancer-related pain in advanced cancer patients. We also postulated that changes in EMG activity in the frontal muscles are related to the reduction in pain perceived by advanced cancer patients. Results from this study may help determine the potential usage and possible mechanisms of EMG biofeedback in pain management for patients with advanced cancer.
n Patients and Method
Study Participants
This study was approved by the institutional review board of Taipei Medical University in Taiwan. All participants provided written informed consent. The study included adult patients (Q18 years old) recruited from a palliative care unit in a medical center located in northern Taiwan who scored 3 or higher on the Taiwanese Version of the Brief Pain Inventory (BPI-T), who had been diagnosed with advanced cancer, and who had been taking pain medications for over 1 week before the study. The prescriptions of pain medication were kept consistent in all patients throughout the study period.
Thirty-seven participants were randomized either to the experimental group (n = 20) or the control group (n = 17). Thirteen patients discontinued (5 died and 8 withdrew) the study, resulting in a total of 24 participants (12 in the experimental and 12 in the control group). The flow of participants is diagrammatically presented in Figure 1 .
Study Design
This was a randomized control trial. The experimental group received 6 EMG biofeedbackYassisted relaxation sessions over a 4-week period, whereas the control group received conventional care. Participants in both groups spent equal amount of time each week with the nurse who performed the biofeedback training to avoid nonspecific effects such as those resulted from increased personal attention.
EMG Biofeedback-Assisted Relaxation Training
Electromyography biofeedbackYassisted relaxation included 6 sessions of EMG biofeedback using the Procomp+/ BioGraph 2.1 biofeedback system (Thought Technology, West Chazy, NY), coupled with relaxation-breathing (ie, deep Figure 1 n Flow of participants in the study. diaphragmatic breathing) training over a 4-week period. Participants were trained by a nurse who had been previously trained by a certified biofeedback therapist, to take slow, deep, and steady breaths, using diaphragm, with minimum possible movement of the chest. Correct diaphragmatic breathing was ensured with the use of the Procomp+ biofeedback apparatus. After ensuing correct practice of diaphragmatic breathing, participants were trained in 6 guided biofeedback sessions. For EMG biofeedback, the electrodes were placed over the frontal area. Participants were asked to breathe deeply and slowly (4Y7 times/min) while observing a visual display of their EMG signals during the first 2 training sessions. The beneficial effects of diaphragmatic breathing were shown by demonstrating fall in frontalis EMG levels after practices. During the last 4 sessions, participants were asked to close their eyes and sit comfortably on a reclining chair while paying attention to auditory EMG feedback signals. With the auditory biofeedback sessions, participants were taught to decrease frontalis EMG potentials by inhibiting the auditory signals. Each session lasted 45 min and consisted of three 7-to 10-min trials. The training criterion was a 20% reduction in the EMG from the pretraining level for 50% of the time in each trial.
Baseline Measurements
Demographic data (age, sex, marital status, and years of education), treatment-related information (types of cancer treatments, cancer pain, and type of analgesics), psychological health, and functional status were assessed at baseline.
Psychological health was assessed using the short form of the Brief Symptom Rating Scale (BSRS-5). The BSRS-5 is a screening tool that facilitates the identification of psychological morbidity. 16 It is composed of 5 questions that assess the severity (from 0 to 4) of 5 common aspects of psychological distress: anxiety, hostility, depression, interpersonal sensitivity, and insomnia, with a score of 0 indicating none to a score of 4 indicating extremely severe. The possible total score ranges from 0 to 20, with a score of 6 being used as the cutoff value.
Functional status was assessed using the Karanofsky Performance Status Scale (KPS). The KPS is a measure of the level of a patient's activity and medical care requirements and has been shown to have good reliability and validity. 17 It is a general measure of patient independence and has been widely used as a general assessment of patients with cancer. 18 The KPS is an ordinal scale that ranges from 0 to 100 at intervals of 10. The lower the score, the lower the functional status.
Outcome Measures
The primary efficacy measure was pain intensity, measured by the BPI-T, a Taiwanese version of the BPI. The BPI-T was assessed in each patient at baseline and after the 4-week training program. The percentages of patients achieving reductions in pain intensity from baseline of at least 30% and at least 50% were also calculated. The BPI is a pain assessment tool commonly used with cancer patients. 19 It contains a series of questions related to pain intensity and its interference with daily life. In this study, we used the intensity subscale of the BPI-T, which is an 11-point (ie, 0Y10) numerical rating scale. The pain intensity subscale of the BPI-T conforms to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendation on the core outcome measure in clinical trials of chronic pain treatments. 20 The BPI asks patients to rate their pain at the time of responding to the questionnaire (pain now) and also at its worst, least, and average. Each question is answered by circling a number between 0 (no pain) and 10 (pain as bad as you can imagine). A pain intensity score is calculated by averaging the total score of the 4 items. Mild pain is defined as 1 to 4; moderate pain, as 5 to 6; and severe pain, as 7 to 10. The BPI-T was developed and validated by Ger and colleagues in 1999 21 and has been shown to have good reliability and validity. In a previous study, we demonstrated that pain intensity as measured by BPI significantly correlated to performance status, as measured by KPS, and mood disturbances, as measured by Profile of Mood States Short Form, in a group of Taiwanese cancer patients. 22 The secondary outcome measure was frontal muscle EMG, which was also assessed at baseline and after the 4-week training program.
Statistical Methods
Baseline comparisons were made using Fisher exact test, chisquare test, and the Mann-Whitney U test. The effects of EMG biofeedbackYassisted relaxation training on pain and frontalis EMG were analyzed using multivariate repeatedmeasures analysis of variance. The relation between the level of pain and muscle tension was tested using the Spearman rank correlation. A P value of less than .05 was considered significant.
n Results Sex, marital status, age, education, cancer treatments received, types of pain, pain intensity, pain medication used, and BSRS-5 and KPS scores did not significantly differ between the experimental and control groups ( Table 1 ). The posttest pain intensity was significantly lower for the experimental group compared with the control group (95% confidence interval = j2.96 to j0.21, P = .011). The experimental group obtained a decrease of 2.29 points in pain intensity from baseline, and the reductions were statistically significant when compared with those of the control group (95% confidence interval = 1.46Y3.79, P G .001). The results of EMG biofeedbackYassisted relaxation for pain reduction are presented in Table 2 . Among the patients in the experimental group, 67% of them obtained a reduction of at least 30% in pain intensity from baseline and 50% obtained a reduction of at least 50% in pain intensity from baseline, whereas the control group had a mean increase of 14% in pain intensity from baseline. Results from the repeated-measures analysis of variance showed a significant time effect (F = 12.69, P = .002) and time-by-group interaction effect (F = 22.8, P G .001) for pain ( Table 3 ), suggesting that the change in the pain level in the experimental group (j2.29) was significantly greater than that in the control group (j0.33). Similarly, the effect of EMG-assisted biofeedback on the frontal muscle EMG was analyzed by repeated-measures analysis of variance. Results showed a significant time-bygroup interaction effect (F = 6.26, P = .021), suggesting that the change in the EMG level in the experimental group at the posttest measurements was significantly greater than that of the control group. Correlational analyses revealed that pretest EMG and pain levels were not significantly correlated (D = 0.15, P = .49), whereas posttest EMG levels significantly correlated with posttest pain levels (D = 0.54, P = .006; Fig. 2 ). In addition, the pretest to posttest change in EMG levels significantly correlated to the change in pain levels (D = 0.47, P = .02, Fig. 3) .
With regard to the percentage of training success, 8 participants (67%) from the experimental group met the predetermined EMG training criterion. A comparison of the characteristics of treatment succeeders and nonsucceeders was performed using the Mann-Whitney U test (Table 4 ). As seen in Table 4 , participants who met the predetermined criterion have a significantly lower BSRS-5 score (mean rank = 4.88) than did those who did not (mean rank = 9.75).
n Discussion This study demonstrates the first evidence that relaxationbreathing training with visual and auditory EMG biofeedback signals is both feasible and effective in reducing cancer-related pain in advanced cancer patients. The efficacy was demonstrated by significantly larger reductions in pain intensity from baseline for the biofeedback group compared with the control group. In the present study, we showed that patients with advanced cancer were able to lower their pain intensity using EMG biofeedbackYassisted relaxation techniques. We also demonstrated that EMG biofeedbackYassisted relaxation significantly changes frontal muscle EMG levels in these patients. The reduction in EMG levels seems to suggest the supposed effectiveness of relaxation through muscular relaxation and, consequently, decreasing anxiety and physiological arousal. A significant correlation between the pretest to posttest changes in the EMG and pain levels further confirms this notion. Although this study did not assess the effect of relaxation-breathing training on anxiety, a recent study has demonstrated the efficacy of a relaxation-breathing exercise on anxiety and depression levels in leukemia patients who were undergoing stem-cell transplantation. 23 Thus, it is likely that EMG biofeedbackYassisted relaxation reduces pain experienced by advanced cancer patients by breaking the pain-anxiety-muscle tension cycle.
Of special notice is that two thirds of the participants in the experimental group met the predetermined training criterion for EMG. This suggests that with adequate training, in this study, consisting of six 45-min sessions, most of the advanced cancer patients were able to obtain the skills necessary to induce the ''relaxation response.'' Analyses of the baseline characteristics of those in the experimental group who completed the treatment showed that succeeders were relatively less psychologically distressed compared with nonsucceeders, as those who met the training criterion had a significantly lower BSRS-5 score than those who did not. The BSRS-5, a simple screening tool for identifying psychological morbidity, may be used to aid the selection of cancer patients who are most likely to benefit from EMG biofeedbackYassisted relaxation. With careful patient selection, EMG biofeedbackYassisted relaxation training may be used along with pain medication for effective pain management for patients with advanced cancer. Learning biofeedback and relaxation skills is likely to enhance a sense of control and self-efficacy, which, in turn, may help individuals cope more effectively with chronic pain. Similar to other patients with chronic pain, cancer patients deal with overwhelming pain on a daily basis. Findings from a previous study suggested that cancer patients choose complementary and alternative medicine therapies supplementary to standard medical treatment as a way to empower themselves and to gain a sense of control. 24 A study assessing the effects of cognitive-behavioral treatment on pain in cancer patients also found that cognitive-behavioral treatment enhanced cancer patients' ability to decrease pain, but not pain intensity or pain distress. 25 We speculated that, similar to other complementary and alternative medicine or cognitive-behavioral treatment therapies, biofeedback-assisted relaxation may alleviate cancer patients' perceptions of pain by enhancing their self-efficacy and ability to cope with pain.
Several limitations existed in this study. First, although participants in both groups spent equal amounts of time each week with the nurse who performed the biofeedback training, it remains likely that the effect of personal attention given to the experimental group might favor the positive outcome. Second, there were slight age differences in both groups in that most participants in the experimental groups were younger than 50 years, whereas in the control group, most participants were older than 50 years. However, after a careful examination of the data, we found that neither the pretest to posttest decrease in pain (both in absolute value and in percentage change) nor the pretest to posttest change in EMG significantly correlated with age (data not shown). Third, the pain intensity varied slightly between groups, and more than 50% of the participants in the control group had mild pain. However, neither the percentage decrease in pain nor the decrease in EMG from pretest to posttest significantly correlated with the baseline pain intensity. Fourth, it should be acknowledged that this study used only 1 efficacy indicator. Thus, the differential effects of the study intervention on multiple dimensions of pain cannot be elucidated in this study. Finally, the cost of the biofeedback-assisted relaxation training program was not estimated, and the longterm effects were not determined in this study. Future studies need to investigate the cost effectiveness of a biofeedbackassisted relaxation program for pain relief in patients with advanced cancer and to study its long-term effects and the possibility of the transfer of the techniques outside the hospital setting.
Although the present study is limited by its small sample size, it demonstrates the potential usefulness of an EMG biofeedbackYassisted relaxation training program in the management of pain in a population with advanced cancer. Future studies need to continue examining mechanisms underlying the efficacy of relaxation training for cancer-related pain.
n Conclusions Electromyography biofeedbackYassisted relaxation training successfully reduces pain of advanced cancer patients possibly through a mechanism of attenuation of physiological arousal. With adequate training, most patients are able to learn the skills necessary to induce the ''relaxation response.'' This is particularly true for those who are not in a state of profound psychological distress. Therefore, in combination with pharmacological treatment, EMG biofeedbackYassisted relaxation training has a great potential to improve the quality of pain management of patients with advanced cancer in palliative care unit.
